0 Replies
-- Collaboration to investigate potential of AtuPLEX™ in the development of novel microRNA therapeutics targeting cancer --
London, UK & Nijmegen/Utrecht, Netherlands, September 12, 2011 –Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V. (“InteRNA”), a biopharmaceutical company developing pathway targeted... Contine Reading & Discuss→
0 Replies
-- Collaboration to investigate potential of DACC in intravenous delivery of siRNAs to the lung --
London, UK, September 27, 2011 –Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, today announces that it has entered into an agreement with one of the world’s leading global... Contine Reading & Discuss→
0 Replies
London, September 20, 2011 – Silence Therapeutics plc (AIM: SLN) (“Silence”, the “Group” or the “Company”), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Thomas Christély as Chief Executive Officer with immediate effect. He will be based at Silence’s facility in Berlin.
Thomas Christély (aged... Contine Reading & Discuss→
0 Replies
SCRIP_shortlist_pressrelease.FINAL_.pdf
Hoersholm, Denmark/San Diego, California, September 28, 2011 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of RNA-targeted therapies utilizing its Locked Nucleic Acid (LNA) Drug Platform, today announced that it has been selected as a finalist for the 2011 Scrip Awards in the... Contine Reading & Discuss→
0 Replies
Stories include:
The University of Michigan's Mohamed El-Sayed, Sophia Merajver and Yasmin Yuksel Durmaz has been awarded a $180,000 grant from Susan G. Komen for the Cure to advance drug-delivery vehicles to transport growth-inhibiting drugs to breast cancer tumors.
InSite Vision has tapped Quintiles to run a Phase III clinical... Contine Reading & Discuss→
0 Replies
Stories include:
@FiercePharma: Merck joins drug cos. looking outside pharma for expertise: New strategy chief from Lenovo Article
Bill Marth, Teva Pharmaceutical Industries' ($TEVA) North American chief, told the Philadelphia Inqurier that the company's planned merger with U.S.-based Cephalon ($CEPH) was still on track despite a newly disclosed federal investigation... Contine Reading & Discuss→
